Halofuginone CAS 55837-20-2
Identification
Properties
Safety Data
Specifications
Links
Identification
CAS Number
55837-20-2
Molecular Structure
structure-of-Halofuginone-CAS-55837-20-2
Name
Halofuginone
Synonyms
4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl]- [ACD/Index Name]
7-Brom-6-chlor-3-{3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl}-4(3H)-chinazolinon [German] [ACD/IUPAC Name]
7-Bromo-6-chloro-3-{3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl}-4(3H)-quinazolinone [ACD/IUPAC Name]
7-Bromo-6-chloro-3-{3-[(2S,3R)-3-hydroxy-2-pipéridinyl]-2-oxopropyl}-4(3H)-quinazolinone [French] [ACD/IUPAC Name]
7-Bromo-6-chloro-3-{3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one
7-bromo-6-chlorofebrifugine
Halofuginone
stenorol
7-Bromo-6-chloro-3-[3-((2RS,3SR)-3-hydroxy-piperidin-2-yl)-2-oxo-propyl]-3H-quinazolin-4-one
7-Bromo-6-chloro-3-[3-((2S,3R)-3-hydroxy-piperidin-2-yl)-2-oxo-propyl]-3H-quinazolin-4-one
empostatin
Halofuginon
17395-31-2(Halofuginone Hydrobromide)
64924-67-0(Halofuginone Hydrobromide)
55837-20-2(halofuginone)
1217623-74-9(Halofuginone hydrochloride)
SMILES
c1c2c(cc(c1Cl)Br)ncn(c2=O)CC(=O)C[C@H]3[C@@H](CCCN3)O
StdInChI
InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m0/s1
StdInChIKey
LVASCWIMLIKXLA-LSDHHAIUSA-N
Molecular Formula
C16H17BrClN3O3
Molecular Weight
414.68
Properties
Appearance
White or off-white powder
Safety Data
Symbol
GHS06, GHS09Signal Word
Danger
Hazard Statements
H300 + H310 + H330-H315-H319-H410
Precautionary Statements
Missing Phrase – N15.00950417-P260-P280-P302 + P352 + P310-P304 + P340 + P310-P305 + P351 + P338
RIDADR
UN2811 – class 6.1 – PG 1 – EHS – Toxic solids, organic, n.o.s., HI: all
WGK Germany
3
RTECS
VA2397066
Specifications and Other Information of Our Halofuginone CAS 55837-20-2
Purity
99.0% min
Identification
HNMR,HPLC
Storage
Under room temperature and away from light
Use
Halofuginone is a coccidiostat used in veterinary medicine. It is a synthetic halogenated derivative of febrifugine, a natural quinazolinone alkaloid which can be found in the Chinese herb Dichroa febrifuga (Chang Shan).Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and it has received orphan drug designation from the U.S. Food and Drug Administration.
Halofuginone inhibits the development of T helper 17 cells, immune cells that play an important role in autoimmune disease, but it does not affect other kinds of T cells which are involved in normal immune function.Halofuginone therefore has potential for the treatment of autoimmune disorders.
Halofuginone is also an inhibitor of collagen type I gene expression and as a consequence it may inhibit tumor cell growth.Halofuginone exerts its effects by acting as a high affinity inhibitor of the enzyme Glutamyl-Prolyl tRNA synthetase. Inhibition of prolyl tRNA charging leads to the accumulation of uncharged prolyl tRNAs, which serve as a signal to initiate the amino acid starvation response, which in turn exerts anti-inflammatory and anti-fibrotic effects.
Links
Caming Link
This product is developed by our RD company Caming Pharmaceutical Ltd (http://caming.com/), focusing on API andamp; Intermediate Technology and here is the corresponding link in Caming
http://caming.com/halofuginone-cas-55837-20-2/
Quick Inquiry
Fill out our inquiry form and one of our experts will be in touch with you shortly.
|
|
  |